Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby, Roger A., Louise Firth, and Edmund J. Lewis. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby, Roger A., Louise Firth, and Edmund J. Lewis
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Blood pressure control reduces the risk of heart disease or stroke among Americans with diabetes by 33-50%.  
  • Every additional dollar spent on statin therapy for diabetes patients without cardiovascular disease has produced health gains valued between $7 and $31.  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in…  
  • LDL-C Screening: Trends, 1998-2006